MELanoma Brain Metastasis Treated With CYberknife
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life. In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma. This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes. Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
Sponsor: European Institute of Oncology
You may qualify if…
- ✓ Age \> 18
- ✓ Written informed consent for treatment and research purposes
- ✓ Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT
- ✓ MBM treatable with stereotactic radiotherapy
- ✓ Systemic therapy (immunotherapy, target therapy, or both) is allowed, as concurrent or non-concurrent treatment with stereotactic radiotherapy
You may not qualify if…
- ✕ Leptomeningeal neoplastic infiltration
- ✕ Previous whole-brain radiotherapy or surgical removal of brain metastases
- ✕ Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma)
Source: ClinicalTrials.gov · NCT07691255 · last updated 2026-09-10